Abstract submissions for the 2020 Joint Australasian HIV&AIDS and Sexual Health Conferences: VIRTUAL close this Sun… https://t.co/i7Wd2BhRHj
ASHM Report Back
Clinical posts from members and guests of the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM) from various international medical and scientific conferences on HIV, AIDS, viral hepatitis, and sexual health.
Treatment Cascade and other snippets
Dr Laura Waters talk on HIV treatment cascade and other HIV population prevention/treatment issues.
2020 goals aiming for 90% of people with HIV diagnosed/90% diagnosed on treatment/90% on treatment undetectable - corresponds to 74% of those with HIV having undetectable viral load.
- Currently (globally) only 32% of those with HIV are on treatment with undetectable VL.
June 2016 paper (Lazarus et al) on adding a “fourth 90” to the 90-90-90-90 targets; that 90% of those on ARVs with undetectable VL have good health-related quality-of-life. Especially pertinent considering incidence of co-morbidities and ageing HIV-infected population (in developed countries).
2016 research from Toronto (Wilton et al) on high-risk populations and perception of risk studied 420 MSM who were objectively high risk:
- 68.3% didn’t perceive themselves to be at moderate to high risk
- 23.6% unaware of PrEP
- 40.1% unwilling to use prep
- 47% lacked a family physician with whom they could discuss HIV issues
Survey of Glasgow2016 audience on new directions for treatment - 40% of attendees believe that non-oral ART will be first-line by 2026.
Transmitted drug resistance by geographical region (START trial) - Australia highest (17.5% had any transmitted drug resistance)